

References

General biology

Molecular Biology of the Cell. 4th ed. Alberts, Bruce; Johnson, Alexander; Lewis, Julian; Raff, Martin; Roberts, Keith; Walter, Peter, New York: Garland Publishing; 2002.

Cancer Medicine. 6th ed. Kufe, Donald W.; Pollock, Raphael E.; Weichselbaum, Ralph R.; Bast, Robert C., Jr.; Gansler, Ted S.; Holland, James F.; Frei III, Emil, editors. Hamilton (Canada): BC Decker Inc. 2003.

Kimball's Biology Pages. J. W. Kimball:
users.rcn.com/jkimball.ma.ultranet/BiologyPages/

Historical

Boveri T. 1914 The Origin of Malignant Tumors ((translated M Boveri, 1929).)
Baltimore, MD: Williams & Wilkins.

Office for National Statistics, Monitor Population & Health, MB 1998/2.

"Jean Astruc (1694-1766): a biography and bibliography," *Journal of the History of Medicine* vol. 15, (1960) pp.184-97

Recherches dur le Traitement du Cancer, etc. Paris. (1829); Editorial Archiv fuer pathologische Anatomie und Physiologie und fuer klinische Medizin 8 (1855) 23].

Hill, J. *Cautions Against the Immoderate Use of Snuff. Founded on the Known Qualities of the Tobacco Plant; And the Effects it Must Produce when this Way Taken into the Body: And Enforced by Instances of Persons who have Perished Miserably of Diseases, Occasioned, or Rendered Incurable by its Use* (R. Baldwin and J. Jackson, London, 1761).

Pott, P. *The Chirurgical Works. Chirurgical Observations Relative to the Cataract, The Polypus of the Nose, The Cancer of the Scrotum, The Different Kinds of Ruptures, and The Mortification of the Toes and Feet* Ch. III 60–68 (Hawes, W. Clarke, and R. Collins, London, 1775).

Theophrasti Paracelsi von Hohenheim. *Von der Bergsucht oder Bergkrankheiten drey Bücher* (Sebaldum Mayer, Dillingen, Germany, 1567).

Celsus, Aulus Arelius Cornelius. *De Medicina*, book V, ch. 28. Translated by Spencer WG. Cambridge, MA: Harvard University Press; 1938, pp. 129,131 [Reprinted in Birmingham, AL: Classics of Medicine Library; 1989, pp. 410-11].

Paul of Aegina. *The Seven Books of Paulus Aegineta*. Translated Adams F. London: Sydenham Society; 1844-7 [As cited in Shimkin MB, *Contrary to Nature: Cancer*, p. 35 (q.v.)].

Colorectal cancer

Fearon ER, Vogelstein B. (1991) A genetic model for colorectal tumorigenesis. *Cell* **61**: 759–767.

Weitz J, Koch M, Debus J, Hohler T, Galle PR, Buchler MW. Colorectal cancer. *Lancet*. 2005 Jan 8;365(9454):153-65.

Stem cells

Bachoo RM, Maher EA, Ligon KL, Sharpless NE, Chan SS, You MJ, Tang Y, DeFrances J, Stover E, Weissleder R, Rowitch DH, Louis DN, DePinho RA. Epidermal growth factor receptor and Ink4a/Arf: convergent mechanisms governing terminal differentiation and transformation along the neural stem cell to astrocyte axis. *Cancer Cell*. 2002 Apr;1(3):269-77.

Cairns J. (2002) Somatic stem cells and the kinetics of mutagenesis and carcinogenesis. *Proc Natl Acad Sci USA* **99**: 10567–10570.

Sharpless NE, DePinho RA. Telomeres, stem cells, senescence, and cancer. *J Clin Invest*. 2004 Jan;113(2):160-8.

Singh S et al., Identification of human brain tumour cells. *Nature*. 2004 432: 396-401.

Genes and cancer

Balmain A, Gray J, Ponder B. The genetics and genomics of cancer. *Nat Genet*. 2003 Mar;33 Suppl:238-44.

Futreal PA, Coin L, Marshall M, Down T, Hubbard T, Wooster R, Rahman N, Stratton MR. A census of human cancer genes. *Nat Rev Cancer*. 2004;4:177-83.

Knudson AG. (2002) Cancer genetics. *Am J Med Genet* **111**: 96–102.

Ma XJ, Salunga R, Tuggle JT, Gaudet J, Enright E, McQuary P, Payette T, Pistone M, Stecker K, Zhang BM, Zhou YX, Varnholt H, Smith B, Gadd M, Chatfield E, Kessler J, Baer TM, Erlander MG, Sgroi DC. Gene expression profiles of human breast cancer progression. *Proc Natl Acad Sci U S A*. 2003 May 13;100(10):5974-9.

Ponder BJ. Cancer genetics *Nature* 2001, 411, 336 - 341

Sweet-Cordero A, Mukherjee S, Subramanian A, You H, Roix JJ, Ladd-Acosta C, Mesirov J, Golub TR, Jacks T. An oncogenic KRAS2 expression signature identified by cross-species gene-expression analysis. *Nat Genet*. 2005 Jan;37(1):48-55. Epub 2004 Dec 19.

van 't Veer LJ, Dai H, van de Vijver MJ, He YD, Hart AA, Mao M, Peterse HL, van der Kooy K, Marton MJ, Witteveen AT, Schreiber GJ, Kerkhoven RM, Roberts C, Linsley PS, Bernards R, Friend SH. Gene expression profiling predicts clinical outcome of breast cancer. *Nature*. 2002 Jan 31;415(6871):530-6.

van de Vijver MJ, He YD, van't Veer LJ, Dai H, Hart AA, Voskuil DW, Schreiber GJ, Peterse JL, Roberts C, Marton MJ, Parrish M, Atsma D, Witteveen A, Glas A, Delahaye L, van der Velde T, Bartelink H, Rodenhuis S, Rutgers ET, Friend SH, Bernards R. A gene-expression signature as a predictor of survival in breast cancer. *N Engl J Med*. 2002 Dec 19;347(25):1999-2009.

Multistage carcinogenesis

Armitage P, Doll R. (1954) The age distribution of cancer and a multi-stage theory of carcinogenesis. *Br J Cancer* **8**: 1–12.

Berenblum I, Shubik P. (1949) An experimental study of the initiating stage of carcinogenesis, and a re-examination of the somatic cell mutation theory of cancer. *Br J Cancer* **3**: 109–118.

Hanahan D and Weinberg RA. (2000). The hallmarks of cancer. *Cell* 100, 57-70.

Land H, Chen AC, Morgenstern JP, Parada LF, Weinberg RA. Behavior of myc and ras oncogenes in transformation of rat embryo fibroblasts. *Mol Cell Biol.* 1986 Jun;6(6):1917-25.

Nowell PC. The clonal evolution of tumour cell populations. *Science.* 1976 Oct 1;194(4260):23-8.

Vogelstein B, Kinzler KW. Cancer genes and the pathways they control. *Nat Med.* 2004 Aug;10(8):789-99.

Oncogenes

Malumbres, M, and Barbacid, M. (2003) *RAS* oncogenes: the first 30 years. *Nature Rev. Cancer* **3**: 7-13.

Downward, J. (2003) Targeting *RAS* signalling pathways in cancer therapy. *Nat. Rev. Cancer* **3**, 11–22

Pelengaris S, Khan M, and Evan G. c-Myc: more than just a matter of life and death. *Nature reviews cancer.* (2002), 2: 764-776.

Pulciani S, Santos E, Lauver AV, Long LK, Aaronson SA, Barbacid M. Oncogenes in solid human tumours. *Nature* 300:539-542;1982.

Strasser A, Harris AW, Bath ML, Cory S. Novel primitive lymphoid tumours induced in transgenic mice by cooperation between myc and bcl-2. *Nature*. 1990 Nov 22;348(6299):331-3.

Shih C, Padhy LC, Murray MJ, Weinberg RA. Transforming genes of carcinomas and neuroblastomas introduced into mouse fibroblasts. *Nature* 290:261-264;1981.

Stehelin D, Varmus H, Bishop M and Vogt P. DNA Related to the Transforming Gene(s) of Avian Sarcoma Viruses Is Present in Normal Avian DNA. *Nature*, 260, 1976: 170–173.

Tumour suppressors

Friend SH, Bernards R, Rogelj S, Weinberg RA, Rapaport JM, Albert DM, Dryja TP. A human DNA segment with properties of the gene that predisposes to retinoblastoma and osteosarcoma. *Nature*. 1986 Oct 16-22;323(6089):643-6.

Kurose K, Gilley K, Matsumoto S, Watson PH, Zhou XP, Eng C. Frequent somatic mutations in PTEN and TP53 are mutually exclusive in the stroma of breast carcinomas. *Nat Genet*. 2002 Nov;32(3):355-7.

Lowe SW, Sherr CJ. Tumor suppression by Ink4a-Arf: progress and puzzles. *Curr Opin Genet Dev*. 2003 Feb;13(1):77-83.

Malkin D, Li FP, Strong LC, Fraumeni JF Jr, Nelson CE, Kim DH, Kassel J, Gryka MA, Bischoff FZ, Tainsky MA, et al. Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. *Science*. 1990 Nov 30;250(4985):1233-8.

Vousden KH, Prives C. P53 and prognosis: new insights and further complexity. *Cell*. 2005 Jan 14;120(1):7-10.

Whyte P, Buchkovich KJ, Horowitz JM, Friend SH, Raybuck M, Weinberg RA, Harlow E. Association between an oncogene and an anti-oncogene: the adenovirus E1A proteins bind to the retinoblastoma gene product. *Nature*. 1988 Jul 14;334(6178):124-9.

Biological study of cancer formation

Adams, J.M. and Cory, S. (1991) Transgenic models of tumour development. *Science*, **254**, 1161–1167.

Berns K, Hijmans EM, Mullenders J, Brummelkamp TR, Velds A, Heimerikx M, Kerkhoven RM, Madiredjo M, Nijkamp W, Weigelt B, Agami R, Ge W, Cavet G, Linsley PS, Beijersbergen RL, Bernards R. A large-scale RNAi screen in human cells identifies new components of the p53 pathway. *Nature*. 2004 Mar 25;428(6981):431-7.

Chin L, Tam A, Pomerantz J, Wong M, Holash J, Bardeesy N, Shen Q, O'Hagan R, Pantginis J, Zhou H, Horner JW 2nd, Cordon-Cardo C, Yancopoulos GD, DePinho RA. Essential role for oncogenic Ras in tumour maintenance. *Nature*. 1999 Jul 29;400(6743):468-72.

Brummelkamp TR, Bernards R. New tools for functional mammalian cancer genetics. *Nat Rev Cancer*. 2003 Oct;3(10):781-9.

Felsher DW. Reversibility of oncogene-induced cancer. *Curr Opin Genet Dev*. 2004 Feb;14(1):37-42.

Hahn, W.C. et al.1999. Creation of human tumour cells with defined genetic elements. *Nature*. **400**:464-468.

Hanahan D. Heritable formation of pancreatic beta-cell tumours in transgenic mice expressing recombinant insulin/simian virus 40 oncogenes. *Nature*. 1985 May 9-15;315(6015):115-22.

Hanahan,D. (1989) Transgenic mice as probes into complex systems. *Science*, **246**, 1265–1275.

Jonkers J, Berns A. Conditional mouse models of sporadic cancer. *Nat Rev Cancer*. 2002 Apr;2(4):251-65.

Jonkers J, Berns A. Oncogene addiction: sometimes a temporary slavery. *Cancer Cell*. 2004 Dec;6(6):535-8.

Karlsson A, Deb-Basu D, Cherry A, Turner S, Ford J, Felsher DW. Defective double-strand DNA break repair and chromosomal translocations by MYC overexpression. *Proc Natl Acad Sci U S A*. 2003 Aug 19;100(17):9974-9.

Knudson AG Jr. Mutation and cancer: statistical study of retinoblastoma. *Proc Natl Acad Sci U S A*. 1971 Apr;68(4):820-3.

Lane DP, Crawford LV. T antigen is bound to a host protein in SV40-transformed cells. *Nature*. 1979 Mar 15;278(5701):261-3.

Olive KP, Tuveson DA, Ruhe ZC, Yin B, Willis NA, Bronson RT, Crowley D, Jacks T. Mutant p53 gain of function in two mouse models of Li-Fraumeni syndrome. *Cell*. 2004 Dec 17;119(6):847-60.

Pelengaris S, Abouna S, Cheung L, Ifandi V, Zervou S, Khan M. Brief inactivation of c-Myc is not sufficient for sustained regression of c-Myc-induced tumours of pancreatic islets and skin epidermis. *BMC Biol*. 2004 Dec 21;2(1):26.

Perl AK, Wilgenbus P, Dahl U, Semb H, Christofori G. A causal role for E-cadherin in the transition from adenoma to carcinoma. *Nature*. 1998 Mar 12;392(6672):190-3.

Rangarajan A, Hong SJ, Gifford A, Weinberg RA. Species- and cell type-specific requirements for cellular transformation. *Cancer Cell*. 2004 Aug;6(2):171-83.

Vogelstein B, Kinzler KW. (2004) Cancer genes and the pathways they control. *Nat Med* **10**: 789–799.

Watnick RS, Cheng YN, Rangarajan A, Ince TA, Weinberg RA. Ras modulates Myc activity to repress thrombospondin-1 expression and increase tumor angiogenesis. *Cancer Cell*. 2003 Mar;3(3):219-31.

Zhu Y, Ghosh P, Charnay P, Burns DK, Parada LF. Neurofibromas in NF1: Schwann cell origin and role of tumour environment. *Science*. 2002 May 3;296(5569):920-2.

Tumour reversal a matter of timing

Boxer RB, Jang JW, Sintasath L, Chodosh LA. Lack of sustained regression of c-MYC-induced mammary adenocarcinomas following brief or prolonged MYC inactivation. *Cancer Cell*. 2004 Dec;6(6):577-86.

Pelengaris S, Abouna S, Cheung L, Ifandi V, Zervou S, Khan M. Brief inactivation of c-Myc is not sufficient for sustained regression of c-Myc-induced tumours of pancreatic islets and skin epidermis. *BMC Biol*. 2004 Dec 21;2(1):26.

Shachaf CM, Kopelman AM, Arvanitis C, Karlsson A, Beer S, Mandl S, Bachmann MH, Borowsky AD, Ruebner B, Cardiff RD, Yang Q, Bishop JM, Contag CH, Felsher DW. MYC inactivation uncovers pluripotent differentiation and tumour dormancy in hepatocellular cancer. *Nature*. 2004 Oct 28;431(7012):1112-7.

Telomeres, instability and chromosomal abnormalities

Blasco MA, Hahn WC. Evolving views of telomerase and cancer. *Trends Cell Biol.* 2003 Jun;13(6):289-94.

DePinho RA, Polyak K. Cancer chromosomes in crisis. *Nat Genet.* 2004 Sep;36(9):932-4.

Greaves M. (2002) Cancer causation: the Darwinian downside of past success? *Lancet Oncol* **3**: 244–251.

Farazi PA, Glickman J, Jiang S, Yu A, Rudolph KL, DePinho RA. Differential impact of telomere dysfunction on initiation and progression of hepatocellular carcinoma. *Cancer Res.* 2003 Aug 15;63(16):5021-7.

Espejel S, Klatt P, Menissier-de Murcia J, Martin-Caballero J, Flores JM, Taccioli G, de Murcia G, Blasco MA. Impact of telomerase ablation on organismal viability, aging, and tumorigenesis in mice lacking the DNA repair proteins PARP-1, Ku86, or DNA-PKcs. *J Cell Biol.* 2004 Nov 22;167(4):627-38.

Feldser DM, Hackett JA, Greider CW. (2003) Telomere dysfunction and the initiation of genome instability. *Nat Rev Cancer.* **3**: 623–627.

Loeb LA. (1991) Mutator phenotype may be required for multistage carcinogenesis. *Cancer Res* **51**: 3075–3079.

Wong KK, Maser RS, Bachoo RM, Menon J, Carrasco DR, Gu Y, Alt FW, DePinho RA. Telomere dysfunction and Atm deficiency compromises organ homeostasis and accelerates ageing. *Nature*. 2003 Feb 6;421(6923):643-8.

Angiogenesis

Hanahan D, Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. *Cell*. 1996 Aug 9;86(3):353-64.

Folkman J. Endogenous angiogenesis inhibitors. *APMIS*. 2004 Jul-Aug;112(7-8):496-507.

Jain RK. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. *Science*. 2005 Jan 7;307(5706):58-62.

Apoptosis and senescence

Argilla D, Chin K, Singh M, Hodgson JG, Bosenberg M, de Solorzano CO, Lockett S, DePinho RA, Gray J, Hanahan D. Absence of telomerase and shortened telomeres have minimal effects on skin and pancreatic carcinogenesis elicited by viral oncogenes. *Cancer Cell*. 2004 Oct;6(4):373-85.

Evan GI, Wyllie AH, Gilbert CS, Littlewood TD, Land H, Brooks M, Waters CM,

Penn LZ, Hancock DC. Induction of apoptosis in fibroblasts by c-myc protein. *Cell*. 1992 Apr 3;69(1):119-28.

Green DR, Kroemer G. The pathophysiology of mitochondrial cell death. *Science*. 2004 Jul 30;305(5684):626-9.

Green DR, Evan GI. A matter of life and death. *Cancer Cell*. 2002 Feb;1(1):19-30.

Lowe SW, Cepero E, Evan G. Intrinsic tumour suppression. *Nature*. 2004 Nov 18;432(7015):307-15.

Nahle Z, Polakoff J, Davuluri RV, McCurrach ME, Jacobson MD, Narita M, Zhang MQ, Lazebnik Y, Bar-Sagi D, Lowe SW. Direct coupling of the cell cycle and cell death machinery by E2F. *Nat Cell Biol*. 2002 Nov;4(11):859-64

Pelengaris S, Littlewood T, Khan M, Elia G, Evan G. Reversible activation of c-Myc in skin: induction of a complex neoplastic phenotype by a single oncogenic lesion. *Mol Cell*. 1999 May;3(5):565-77.

Pelengaris S, Khan M, Evan GI. Suppression of Myc-induced apoptosis in beta cells exposes multiple oncogenic properties of Myc and triggers carcinogenic progression. *Cell*. 2002 May 3;109(3):321-34.

Inflammation, immunity and cancer

Blattman JN, Greenberg PD. (2004) Cancer immunotherapy: a treatment for the masses. *Science* **305**: 200–205.

Greten FR, Eckmann L, Greten TF, Park JM, Li ZW, Egan LJ, Kagnoff MF, Karin M. IKKbeta links inflammation and tumorigenesis in a mouse model of colitis-associated cancer. *Cell*. 2004 Aug 6;118(3):285-96.

Curiel TJ, et al., Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. *Nat Med*. 2004, 10(9):942-9.

Metastases

Bernards R and Weinberg R. A progression puzzle. (2002) *Nature* 418: 823-824

Crnic I, Christofori G. Novel technologies and recent advances in metastasis research. *Int J Dev Biol*. 2004;48(5-6):573-81.

Shevde LA, Welch DR. Metastasis suppressor pathways--an evolving paradigm.

Steege PS. Metastasis suppressors alter the signal transduction of cancer cells. *Nat Rev Cancer*. 2003 Jan;3(1):55-63.

Yang J, Mani SA, Donaher JL, Ramaswamy S, Itzykson RA, Come C, Savagner P, Gitelman I, Richardson A, Weinberg RA. Twist, a master regulator of morphogenesis, plays an essential role in tumor metastasis. *Cell*. 2004 Jun 25;117(7):927-39.

Cancer Profiling and ‘tailored’ medicine

Carr KM, Rosenblatt K, Petricoin EF, Liotta LA. Genomic and proteomic approaches for studying human cancer: prospects for true patient-tailored therapy. *Hum Genomics*. 2004 Jan;1(2):134-40.

Celis JE, Moreira JM, Gromova I, Cabezon T, Ralfkiaer U, Guldborg P, Straten PT, Mouridsen H, Friis E, Holm D, Rank F, Gromov P. Towards discovery-driven translational research in breast cancer. *FEBS J*. 2005 Jan;272(1):2-15.

Petros WP, Evans WE. Pharmacogenomics in cancer therapy: is host genome variability important? *Trends Pharmacol Sci*. 2004 Sep;25(9):457-64.

Screening and prevention

Hakama M, Miller AB, Day NE. Screening for cancer of the uterine cervix. Lyon: IARC, 1986

Hahn M., Saeger H.D., Schackert H.K. (1999). Hereditary colorectal cancer: clinical consequences of predictive molecular testing. *International Journal of Colorectal Disease*. 14: 184-193.

Miller AB. Cervical cancer screening programmes. Geneva; WHO, 1992.

Sasieni et al. *British Journal of Cancer*. 1996, vol 73, 1001 – 1005.

Sass J.O., Pascoe-Gonzales S., Lehnert W. (2002). Screening in clinical trials. *The Lancet*. 360: 952.

Stewart BW, Coates AS. Cancer prevention: a global perspective. *J Clin Oncol*. 2005 Jan 10;23(2):392-403.

Willis CM, Church SM, Guest CM, Cook WA, McCarthy N, Bransbury AJ, Church MR, Church JC. Olfactory detection of human bladder cancer by dogs: proof of principle study. *BMJ*. 2004 Sep 25;329(7468):712.

Distant effects of cancer

Stewart AF. Clinical practice. Hypercalcemia associated with cancer. *N Engl J Med*. 2005 Jan 27;352(4):373-9.